My very own thread ehhh… but unfortunately the conspirator accusations are well off the mark. I believe ANP is a quality spec overlooked by the wider market and I’m happy to voice and challenge for debate etc when time allows. Nothing more nothing less.
Sometimes when logic shows its face it can be hard-hitting for those watching on the sidelines – most traders around here know ANP has been given a raw deal MC wise - you only need to look at what USA markets value the drugs at to see that. I upset the swing traders when I talk up ANP against their positions lol that has become obvious... the swing traders on this thread have become shameless in how they conduct themselves! I simply put them under pressure from time to time. If you don’t like my posts simply put me on ignore.
Unfortunately for ANP after 1101 & 1102 being deemed as “dusters” by most – traders/investors have since looked past what fundamentally makes 1103 different. I never invested for 1101/02 for my own reasons.. but you only need to see that ANP has had big pharma wanting in on 1103 before they even planned P1 trials to see that the concept is highly investable even from the very early stages.
Prior to PI approach by pharma… a Pharmaceutical Company that has previously expressed an interest in ATL103 has indicated to ANP its desire to move into licensing due diligence.
ISIS have tried to make ANP with 1103 - after 2 “perceived” flops and that comment above a blind man can see they could have licenced 1103 to others for multiples of our current MC and at PRE-clinical stages - so why give it to ANP then?? This one/drug isn’t so much in need of the “R&D” the others are in the ISIS pipeline… it has a clear and well known pathway ahead. KISS especially when you’re a junior - that is where they went wrong previously. That is part of what feeds my bullishness on ANP!
Gassy/Kpkg… all good still watching closely and not much to add really. All I’d say is to be honest I’d rather see more funds put further into 1103 than 1102 at this stage… and again a good reduction of IGF on a modest dose sees this drug likely at the FDA for finial approvals at some stage... whether it is ANP still holding the deeds or not 1103 has a REAL hope of going all the way.
Re the SP to be honest and as mentioned here by others US markets obviously rate Antisense a whole lot different to what oz do. My previous claims that we could reach heights of 20c pre-consolidation were substantiated with my reasons why at the time.. and given what some bios are trading at with what I consider to be a lot less substance i'd stand by that today also.
I think the consolidation is well needed and it is a good time to do it now. Bios have been doing well over the past 12 months post-consolidation just refer to ISN, CGP, BLT just to name a few that come to mind.
Anyway enough for now got to run so cheerio, Godspeed and good day folks!
ANP Price at posting:
13.0¢ Sentiment: LT Buy Disclosure: Held
